Synapse - Works

Results (5608)

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Meeting Abstract

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade

Meeting Abstract

Reese, S. W.; Jiang, H.; Kuo, F.; Wu, C. Y.; Vuong, L.; Mascareno, E.; Oparanozie, A.; Motzer, R. J.; Voss, M. H.; Reznik, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Extended follow-up results from the CheckMate 274 trial

Meeting Abstract

Galsky, M. D.; Witjes, A. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; Park, S. H.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk

Meeting Abstract

Powles, T.; Motzer, R. J.; Albiges, L.; Suárez, C.; Schutz, F. A. B.; Heng, D. Y. C.; Chevreau, C.; Kanesvaran, R.; Gurney, H.; Wang, F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Shah, N. J.; Campbell, M. T.; Mao, S. S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H. J.; Keshava-Prasad, H.; Yan, H.; Esquibel, V.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101

Meeting Abstract

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Uemura, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Huang, B; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC)

Meeting Abstract

Choueiri, T. K.; Motzer, R. J.; Powles, T.; Burotto, M.; Apolo, A. B.; Escudier, B.; Tomita, Y.; McDermott, D. F.; Braun, D. A.; Han, C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214

Meeting Abstract

Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development

Meeting Abstract

Gaffney, C.; Jiang, S.; de Jesus, M. R.; Chu, C. E.; Benfante, N.; Bajorin, D. F.; Donahue, T. F.; Rosenberg, J. E.; Iyer, G.; Bochner, B. H.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial

Meeting Abstract

Burotto, M.; Powles, T.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save